Achaogen, Inc.

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

The US FDA’s approval of two novel antifungals for women with vulvovaginal candidiasis in a little over a year – plus a significant new claim already under review – gives the common yeast infection a

Basilea Pharmaceutica Ltd. unveiled positive Phase III results for ceftobiprole in Staphylococcus aureus bacteremia (SAB), on top of existing Phase III data for the drug in acute bacterial skin and

Entasis Therapeutics Holdings Inc. hopes to be the first company to obtain a pathogen-specific indication from the US Food and Drug Administration with a broad claim for its antibacterial combination